Lipoproteins, stroke and statins

Area of Science:

• Cardiovascular Medicine
• Neuroscience
• Pharmacology

Background:

• Dyslipidemia is a primary risk factor for atherosclerosis, impacting cerebral, cardiac, and peripheral arteries.
• Atherosclerosis contributes significantly to morbidity and mortality, particularly coronary artery disease and cerebral stroke in middle-aged and elderly populations.

Purpose of the Study:

• To review the role of various lipoproteins (triglycerides, HDL-C, LDL-C, Lp(a)) in stroke pathogenesis.
• To highlight the efficacy of statins in managing hyperlipidemia and mitigating stroke risk.

Main Methods:

• Literature review focusing on dyslipidemia, atherosclerosis, and stroke.
• Analysis of the impact of lipid fractions on cardiovascular and cerebrovascular events.
• Examination of the therapeutic role of statins in lipid modification and risk reduction.

Main Results:

• Specific lipoproteins like LDL-C and Lp(a) are implicated in the development of stroke.
• Statins effectively reduce lipid levels and have demonstrated a significant impact on decreasing cardiovascular events.
• Hypolipidemic drugs, including statins, can prevent, slow, or even reverse atherosclerotic plaque progression.

Conclusions:

• Lipid management through lifestyle changes and pharmacotherapy, particularly statins, is crucial for reducing stroke and cardiovascular disease.
• Understanding the role of specific lipoproteins is key to developing targeted strategies for stroke prevention.
• Statins offer a powerful therapeutic option for managing dyslipidemia and lowering the risk of atherosclerotic complications.